We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.55 | 0.44% | 125.14 | 3,080 | 09:13:02 |
--Germany could consider banning the export of Novo Nordisk's Ozempic drug amid a shortage of the medication for diabetes patients, the head of the country's federal institute for drugs and medical devices tells Der Spiegel in an interview. Ozempic is approved for diabetes treatment but is also being used "off-label" as a weight-loss medication.
--The institute's president, Karl Broich, says that Ozempic is cheaper in Germany than in some other countries and that some supply is ending up in other European countries or the U.S., the magazine reports.
--"We need the drug for the treatment of diabetes patients and not as a life-style medication," he says, adding that if current measures don't work, a ban could be considered, according to Der Spiegel.
Full story in German: https://tinyurl.com/2bzrm5by
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
November 15, 2023 09:35 ET (14:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions